Circuit-Based Deep Brain Stimulation for Parkinson's Disease P1A2&3 Catalyst

Parkinson Disease Clinical Trial

Official title:

Circuit-Based Deep Brain Stimulation for Parkinson's Disease P1A2&3 Catalyst

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05658302
• Other study ID #: STUDY00015253
• Status: Recruiting
• Start date: March 28, 2023
• Est. completion date: March 1, 2027

Study information

• Verified date: February 2024
• Source: University of Minnesota
• Contact: Michael Park, PhD, MD
• Phone: 612-626-4706
• Email: mcpark[@]umn.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will help us better understand how the brain works in people with Parkinson's disease (PD). PD is a brain disease that gets worse over time, and affects over 10 million people world-wide. A common treatment for PD is Deep Brain Stimulation (DBS). To improve DBS therapy for PD, we need a deeper understanding of how the different parts of the brain work together in PD, and how this relates to movement and thinking problems that people with PD experience.

We may be able to use the results of this study to improve DBS treatments in the future.

Description:

Parkinson's disease (PD) is a progressive neurodegenerative disease affecting over 10 million people world-wide. It can be a debilitating disorder and although studied for decades, the physiological changes in the basal ganglia thalamocortical (BGTC) circuit that underlie its development remain under debate. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) and internal globus pallidus (GPi) has been a highly effective therapy for many patients with PD, however, the results have been highly variable and may be associated with cognitive compromise in some patients. To advance DBS therapies for PD we require a deeper understanding of the local and network-wide circuit dynamics and their relationship to motor signs and cognitive function. This understanding will provide the rationale for optimizing STN and GPi DBS, targeting specific regions within the STN and GPi, and development of patient-specific DBS based on the patients' motor signs and cognitive profile

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 1, 2027
• Est. primary completion date: March 1, 2026
• Gender: Female
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of idiopathic PD

• Surgery at UMN to implant DBS system with directional lead(s) and multiple independent current control IPG is planned as part of routine clinical care

• At least 21 years old

• Existing or planned 7T brain imagery

Exclusion Criteria:

• Other significant neurological disorder

• History of dementia

• Patients with post-operative complications or adverse effects (e.g. ON stimulation dystonias) that affect patient safety or confound the experiment will be excluded from further study

• Pregnant women

• Known radiation exposure within the last year that is determined to be unsafe when compounded with the expected radiation dose from intraoperative fluoroscopy to place ECoG strip

Related Conditions & MeSH terms

• Parkinson Disease

Locations

Country	Name	City	State
United States	University Of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	reach-related modulation	reach-related modulation in beta/HFO power in DBS lead LFPs across OFF, DBS, L-dopa, and DBS+L-dopa conditions.	2 days
Primary	N-back task trials	directed connectivity between STN and DLPFC compared between the N-back task trials with and without stimulation.	2 days
Primary	rigidity and bradykinesia assessments	differences in rigidity and bradykinesia assessments between conditions: off-stimulation vs eiDBS-suppression, off-stimulation vs eiDBS-amplification, eiDBS-suppression vs eiDBS-amplification.	1 day
Primary	peak frequency of the ERs + spontaneous LFPs	the correlation between the peak frequency of the ERs in the GPi (or STN) and that of spontaneous LFPs in the GPi (or STN).	1 day
Secondary	N-back task trials	difference in directed connectivity between the correct reject N-back COGED trials across OFF, DBS, L-dopa, and DBS+L-dopa conditions, as well as measures of directed connectivity between STN/GPi and other ECoG sites (SC/MC/PMC/DLPFC) correlated to the N-back task trials correct response performance across the conditions mentioned above.	2 days
Secondary	rigidity/bradykinesia measurements and correlations to conditions	correlations between each of the rigidity/bradykinesia measurements and the following: 1) amplitude of beta band oscillations in the STN or GPi and 2) information flow between the GPi (or STN) and cortical regions, and 3) PAC. Other secondary outcomes on Day 3 include 1) the coherence between ERs in the GPi or STN and ERs observed in the MC, PMC, and DLPFC; and 2) the correlation of pathway-activation measures (AFtotal) with the amplitude of ERs in the GPi (or STN) across both stimulation settings and patients.	1 day
Secondary	task vs. rest and topographical location	task vs. rest, and topographical location, within each of the conditions.	2 days